Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

Second death linked to Sarepta Therapeutics treatment leaves Duchenne muscular dystrophy community reeling, Elevidys use halted in non-ambulatory patients.

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t getting answers from Sarepta.

In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...

Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ...

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD ...

The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving ...

The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...

Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

Duchenne muscular dystrophy affects approximately 15,000 people in the United States, primarily boys. The genetic disorder disrupts production of dystrophin, a protein essential for muscle function.

Like the first death reported in March, Sarepta Therapeutics attributed the fatality to a case of acute liver failure following dosing of the Duchenne muscular dystrophy gene therapy, Elevidys ...